Pinealon
Pinealon is a peptide, indexed here under Short peptide bioregulators.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Short peptide bioregulators |
| CAS registry number | 175175-23-2[1] |
| PubChem CID | 10273502[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C15H26N6O8[1] |
| Molecular weight | 418.4 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Pinealon is the synthetic tripeptide Glu-Asp-Arg, one of the short peptide bioregulators developed in St Petersburg. A 2011 Rejuvenation Research paper reports increased cell viability through suppression of free radical levels and activation of proliferative processes in its model, and a 2019 Journal of Physical Chemistry B paper reports the role of mono- and divalent ions in the interaction of the Glu-Asp-Arg peptide with DNA.
The animal records are rat studies: a 2012 International Journal of Clinical and Experimental Pathology paper on offspring of dams with prenatal hyperhomocysteinaemia, a 2014 Advances in Gerontology paper on serum cytokines and brain caspase-3 activity in old rats under acute hypoxia, and a 2015 paper in the same journal on the influence of pinealon and cortexin on behaviour and neurochemical processes in 18-month-old rats under hypoxia and hypothermia.
[3, 4, 5, 6, 7]Reported mechanism
A tripeptide bioregulator; the retrieved records report an interaction with DNA and suppression of free radical levels in cells, with no receptor target named.
[4, 3]Stated in the titles of the cited 2019 Journal of Physical Chemistry B and 2011 Rejuvenation Research papers.
Targets named in the cited records: DNA binding, free radical levels.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Pinealon appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- Glu-Asp-Arg
- EDR peptide
Where this page sits
Research records
Cited research records for Pinealon, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Cortexin — Short peptide bioregulators
- Epitalon — Mitochondrial and longevity-associated peptides
- Cortagen — Short peptide bioregulators
Class page: Short peptide bioregulators. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Pinealon?
Pinealon is the synthetic tripeptide Glu-Asp-Arg, one of the short peptide bioregulators developed in St Petersburg. A 2011 Rejuvenation Research paper reports increased cell viability through suppression of free radical levels and activation of proliferative processes in its model, and a 2019 Journal of Physical Chemistry B paper reports the role of mono- and divalent ions in the interaction of the Glu-Asp-Arg peptide with DNA.
Which class is Pinealon indexed under?
Pinealon is indexed under Short peptide bioregulators. This class groups the short synthetic peptides and tissue polypeptide extracts developed by the St Petersburg bioregulator programme, which research-peptide catalogues sell as a family.
What does the FDA application register show for Pinealon?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 10273502, Glu-Asp-Arg. PubChem, National Library of Medicine (2026). pubchem:10273502
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:pinealon
- Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation research (2011). pmid:21978084
- Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. The journal of physical chemistry. B (2019). pmid:30762356
- Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International journal of clinical and experimental medicine (2012). pmid:22567179
- [Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]. Advances in gerontology = Uspekhi gerontologii (2014). pmid:25051764
- [Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]. Advances in gerontology = Uspekhi gerontologii (2015). pmid:28509493
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.